Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Centessa Pharmaceuticals plc Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences November 04, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) September 26, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares September 12, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares September 11, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers September 10, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) August 27, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference August 21, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 August 13, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer June 10, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences May 21, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 May 13, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares April 23, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares April 23, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 April 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 March 28, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference February 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and February 09, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences January 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference December 13, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia December 10, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 November 13, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting November 02, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors October 31, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences October 30, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders October 25, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces Additions to Senior Leadership Team October 03, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference August 31, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress August 23, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 August 14, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors July 10, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Tickers CNTA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
